DNLI cites strong AVLAYAH launch and pipeline progress
Denali Therapeutics highlighted a strong AVLAYAH launch, robust pipeline progress, and global expansion plans, with key program data readouts expected in 2027–2028. Strategy centers on a multi-product enzyme franchise and advancing Alzheimer’s and FTD programs.